Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fulgent Genetics Inc (NQ: FLGT )

16.95 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fulgent Genetics Inc

< Previous 1 2 3 4 5 6 7 8 Next >
Can This Stock Grow Despite a COVID Testing Decline?
Fulgent has capitalized on COVID-19 testing, but even though this segment of its business might slow, there are plenty of reasons to own the company. 
Via The Motley Fool
Exposures COVID-19
These 3 Top Healthcare Stocks Are Screaming Buys Right Now
If the market crashes these companies could be insulated. 
Via The Motley Fool
Fulgent Genetics to Partner with Houston Health Department and Houston-Area Public Schools on Back-to-School COVID-19 Testing Program
From Fulgent Genetics, Inc.
Via Business Wire
3 Unstoppable Healthcare Stocks to Buy With Just $1,000
It doesn't take much when you buy great companies and let them grow. 
Via The Motley Fool
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
While You're Waiting For That Elusive Silver Squeeze...
You may be missing an actual squeeze elsewhere. 
Via Talk Markets
The 1 Stock I'd Buy Right Now
The pandemic isn't over yet. 
Via The Motley Fool
Exposures COVID-19
Fulgent Genetics's Return on Invested Capital Overview
Pulled from Benzinga Pro data, Fulgent Genetics (NASDAQ:FLGT) posted Q2 earnings of $98.90 million, an increase from Q1 of 62.95%. Sales dropped to $153.62 million, a 57.26%... 
Via Benzinga
10 Million Reasons I'm Not Selling Fulgent Genetics
The company is about to shock Wall Street. 
Via The Motley Fool
Exposures COVID-19
Have $500? 3 Absurdly Cheap Healthcare Stocks Long-Term Investors Should Consider Buying Right Now
Everyone loves a discount. 
Via The Motley Fool
2 Types of Growth Stocks Investors Should Be Holding in Their Portfolios Today
Hedging against COVID-19 could prove to be crucial in keeping your portfolio safe. 
Via The Motley Fool
Topics Economy
Exposures COVID-19 Economy
85 Biggest Movers From Yesterday
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX... 
Via Benzinga
Why Shares of Fulgent Genetics Are Plunging Today
Spectacular quarterly results were not enough to satisfy investors' appetites. 
Via The Motley Fool
Topics Death
Exposures COVID-19 Death
54 Stocks Moving In Tuesday's Mid-Day Session
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) climbed 79.3% to $14.93 after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Arcturus Therapeutics (NASDAQ:ARCT) shares rose 25.93% to $60.75 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.5... 
Via Benzinga
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures COVID-19
28 Stocks Moving in Tuesday's Pre-Market Session
Gainers Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares rose 38.6% to $66.88 in pre-market trading after the company reported better-than-expected Q2 earnings and also... 
Via Benzinga
Fulgent Genetics Stock Falls As Q2 Earnings Miss Street Estimates; Lowers FY21 Sales Outlook
Fulgent Genetics Inc (NASDAQ: FLGT) reported after the close of the market on Monday that its second-quarter revenues increased nearly ninefold, driven primarily by... 
Via Benzinga
Topics Earnings
Exposures Financial
Fulgent Genetics, Inc. Common Stock (FLGT) Q2 2021 Earnings Call Transcript
FLGT earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Recap: Fulgent Genetics Q2 Earnings
Shares of Fulgent Genetics (NASDAQ:FLGT) decreased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 1400.00% year... 
Via Benzinga
Fulgent Genetics Reports Second Quarter Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Genetics and Helio Health Announce Strategic Partnership to Commercialize Early Cancer Detection Tests
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Genetics Announces Acquisition of CSI Laboratories
From Fulgent Genetics, Inc.
Via Business Wire
CORRECTING and REPLACING Fulgent Genetics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Genetics to Announce Second Quarter 2021 Financial Results on Thursday, August 5, 2021
From Fulgent Genetics, Inc.
Via Business Wire
Why Shares of Fulgent Genetics Rose 77% in the First Half of 2021
The stock has traded with the ebbs and flows of COVID cases, but its testing has consistently delivered for its impressive list of customers. 
Via The Motley Fool
3 Things About Fulgent Genetics That Smart Investors Know
Few companies had bigger tailwinds from COVID-19. What comes next could be even more exciting. 
Via The Motley Fool
Exposures COVID-19
5 Stocks to Own for the Surge in Coronavirus Variants
Despite easing restrictions, COVID is going to be around a lot longer than many think. 
Via The Motley Fool
Exposures COVID-19
3 Stocks I'd Buy if the Market Crashes
A steep sell-off is required for these stocks to become bargain buys. 
Via The Motley Fool
Is It Too Late to Buy Fulgent Genetics Stock?
All is not lost for this COVID-19 testing company. 
Via The Motley Fool
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.